Prostate Cancer Foundation (PCF) provides support for prostate cancer research. The foundation raises donations from corporations, individuals, and others and then awards grants to cancer researchers searching for new prostate cancer treatments. It also supports cancer research centers that work together to facilitate faster prostate cancer research. PCF was founded in 1993 and is based in Santa Monica, California.
1250 Fourth Street
Santa Monica, CA 90401
Founded in 1993
Prostate Cancer Foundation Presents at Milken Institute Global Conference 2014, Apr-29-2014 03:45 PM
Apr 27 14
Prostate Cancer Foundation Presents at Milken Institute Global Conference 2014, Apr-29-2014 03:45 PM. Venue: Lon Angeles, California, United States. Speakers: Howard R. Soule, Chief Science Officer.
Prostate Cancer Foundation, Cedars-Sinai Medical Center and Johns Hopkins Medicine, Inc. Announces the Launch of National Proactive Surveillance Network
Oct 24 12
The Prostate Cancer Foundation (PCF), Johns Hopkins Medicine and Cedars-Sinai Medical Center announced the launch of the National Proactive Surveillance Network (NPSN), an online resource for men diagnosed with low-grade prostate cancer, which can be slow growing and non-life threatening in up to 50% of diagnosed cases. The network is structured to actively manage prostate cancer in patients who qualify for a non-intervening management program, known as proactive surveillance. The program will use protocols developed by urologists at Johns Hopkins Medicine. The network includes myConnect, an interactive patient portal designed to track the progress of a patient's treatment, connect patients with network physicians, and receive proactive surveillance alerts. The service is HIPAA compliant for patient privacy and security. In the future, myConnect will allow patients to schedule appointments, and track their progress with interactive charts and graphs. Patients who join the National Proactive Surveillance Network will undergo biannual digital rectum exams (DRE), urine tests and PSA tests, as well as a yearly prostate biopsy. Patients will also answer lifestyle and nutrition questionnaires and record their medical history. In addition to providing an efficient model for proactive surveillance, the network will collect and sort data in a scientific-blinded fashion--with absolutely no patient name association--so researchers can analyze trends and the success of the program. Patient samples, including blood and urine, will also be analyzed and banked by Johns Hopkins Medicine on the east coast and Cedars-Sinai Medical Center in the west with patient consent. The repository of blood and urine will support future biomarker and genetic studies.